Orthofix' BoneSource slated for limited release in August by Howmedica Leibinger.
This article was originally published in The Gray Sheet
Executive Summary
ORTHOFIX BONESOURCE HA CEMENT SHIPMENTS TO BEGIN IN AUGUST by licensee Howmedica Leibinger to U.S. and European surgeons who are trained in the use of the material; a full-scale release is projected for later this year. BoneSource hydroxyapatite (HA) cement received 510(k) clearance June 27 and will be used initially as a bone substitute in repairing skull deformities and filling cranial defects.
You may also be interested in...
Orthofix, Stryker Preparing To Capitalize On Growing Bone Graft Market
Orthofix is looking to benefit from a growing bone graft market as development and marketing partner Stryker expands indications for Orthofix' BoneSource bone substitute material.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.